AI and Drug Development: IP and data protection challenges

Artificial intelligence (AI) is not new to the life sciences industry but its use in drug development is rapidly growing, as life sciences companies increasingly recognize the benefits of...

HHS anti-kickback and Stark proposed rules: Impact on value-based care and longstanding regulatory hurdles

CMS and OIG proposed wide-ranging protections for value-based arrangements and provided guidance on a number of regulatory challenges under the AKS and Stark Law. On November 14, join us...

Silicon Valley: Life Sciences and Health Care Horizons 2019

Join us in Silicon Valley: Local insights for global reach

Tech - Exposed in a downturn

Tech has been transformed in the last decade. Does value invested in the cloud, big data and algorithms create new risks and opportunities if there is an economic downturn. If so, what...

Tokyo: Life Sciences and Health Care Horizons 2019

Key Life Sciences issues for Japanese companies: focus on (1) digital health, (2) cell, tissue, and gene therapies, and (3) cross-border transactions.

Tokyo: Life Sciences and Health Care Horizons 2019

Key Life Sciences issues for Japanese companies: focus on (1) digital health, (2) cell, tissue, and gene therapies, and (3) cross-border transactions.

A turning point for Tech

Are politics and regulation fundamentally changing the climate for tech? Join us to explore what's happening, what's coming and what it means for businesses, investors and...

Boston Compliance Forum 2019

The Hogan Lovells Boston team along with regional and international colleagues is hosting an informative breakfast forum in Cambridge, MA on October 29, 2019. The event features two...

Loading data